Heterogeneity of Response to Methylphenidate in Apathetic Patients in the ADMET 2 Trial.

Krista L Lanctôt,Luc Rivet,Shankar Tumati,Jamie Perin,Krushnaa Sankhe,Danielle Vieira,Jacobo Mintzer,Paul B Rosenberg,David Shade,Alan J Lerner,Prasad R Padala,Olga Brawman-Mintzer,Christopher H van Dyck,Anton P Porsteinsson,Suzanne Craft,Allan I Levey,Kalpana P Padala,Nathan Herrmann

Alzheimer's & Dementia（2023）

引用 1|浏览7

暂无评分

摘要

Individuals who were not anxious or agitated, younger, prescribed a ChEI, with optimal (73-80 mm Hg) diastolic blood pressure, or having more impaired function were more likely to benefit from methylphenidate compared to placebo. Clinicians may preferentially consider methylphenidate for apathetic AD participants already prescribed a ChEI and without baseline anxiety or agitation.

查看译文

关键词

Methylphenidate,apathy,stimulants,predictors of response

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要